Teva Oral Copaxone Could Be Studied At Higher Dose After Interim Analysis
Teva is considering conducting a Phase III trial evaluating a higher dose of oral Copaxone (glatiramer acetate) after an interim analysis of Teva's Phase III study of the oral formulation suggested that the trial will not meet its endpoints.
You may also be interested in...
Ivax and Serono hope to launch pivotal trials for their oral multiple sclerosis therapy Mylinax (cladribine) in late 2004
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011